Septerna, Inc.

NASDAQ:SEPN

Biotechnology

Healthcare
$39.45 -2.04%

-$0.73 today

Market cap
$1.88B
Beta
2.38
P/E (TTM)
-43.6
EPS (TTM)
-$0.81
52W Low $9.96High $37.32

Volume 0.30M

Average 0.32M

SEPN Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Septerna, Inc.NASDAQ: SEPN

Net Change in Cash · Q3 FY2026 · quarter ended Sep 2026

Net change in cash declines year over year

Q3 FY2026 net change in cash of $82.46M fell 36.9% year over year, ahead of the -166.0% change in trailing-twelve-month net change in cash. Sequentially, it rose 531.6% from the prior quarter.

Context

  • Net change in cash amounted to 255.7% of revenue in FY2025, down 13671.1 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -36.9% holds above the trailing-twelve-month pace of -166.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$82.46M+531.6% QoQ
Last fiscal yearDec 2025
-$117.47M-178.5% YoY
LTMSep 2026
-$152.87M-166.0% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.9%——
1 year-178.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(117.47M) USD
Year-over-year change
-178.5%

Net Change in Cash vs competitors

How SEPN compares with its peers on the latest reported figures

  • SEPN's LTM Sep 2026 net change in cash of $152.87M is the 2nd largest of the 7 companies compared; the peer median is $37.69M.
  • Its year-over-year change of -166.0% is the 5th highest of 6, against a peer median of +52.5%.
  • Net change in cash amounts to 158.8% of revenue for SEPN, versus a peer median of 330.0%.
SEPN Competitors Peer median
Net Change in Cash for SEPN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$357.83M +52.5%——
SEPNSepterna, Inc.LTM Sep 2026$152.87M -166.0%—158.8%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$95.61M -136.2%-57.8%478.0%
VTVTvTv Therapeutics Inc.LTM Mar 2026$67.03M +416.2%—181.9%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$61.23M -167.8%+31.0%—
KLRAKailera Therapeutics, Inc.FY2025$14.15M ———
BMEABiomea Fusion, Inc.LTM Mar 2026$9.2M +108.4%-58.2%—
Peer median (excluding SEPN) $37.69M+52.5%-57.8%330.0%

Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.68M)4.18M(71.8M)(48.88M)
Depreciation & Amortization577K848K1.4M1.6M
Deferred Income Tax0491K(491K)0
Stock-Based Compensation1.52M1.62M3.15M8.48M
Change in Working Capital1.75M926K248K162.78M
Accounts Receivables0(151K)(20K)(10.19M)
Inventory0000
Accounts Payables1.73M(653K)723K6.6M
Other Working Capital20K1.73M(455K)166.36M
Other Non-Cash Items530K(46.79M)18K(13.79M)
Operating Cash Flow(23.3M)(38.72M)(67.47M)110.19M
Capital Expenditures(1.29M)(2.88M)(2.1M)(518K)
Acquisitions (Net)00012.5M
Purchases of Investments00(213.39M)(450.95M)
Sales of Investments0032.27M209.62M
Other Investing Activities025M22.63M0
Investing Cash Flow(1.29M)22.12M(160.6M)(229.35M)
Debt Repayment0000
Common Stock Issued82K0302.79M1.69M
Common Stock Repurchased0(1K)(1K)(1K)
Dividends Paid0000
Other Financing Activities0052K0
Financing Cash Flow30.05M74.52M377.78M1.69M
Effect of Forex Changes0000
Net Change in Cash5.46M57.92M149.71M(117.47M)
Free Cash Flow(24.59M)(41.6M)(69.57M)109.67M

Septerna, Inc.

NASDAQ:SEPN

Intrinsic Alpha fair value

Locked

Current Price

$39.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.